Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faslodex vs Nolvadex in advanced breast cancer
NCT00241449Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 1998
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of fulvestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to disease progression. Started Nov 1998; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00241449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241449.